Bio Blast Pharma (ORPN) Given Media Impact Rating of 0.21

News coverage about Bio Blast Pharma (NASDAQ:ORPN) has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bio Blast Pharma earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0982301939659 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

• Trading summary on Bioblast Pharma Ltd. (ORPN) – Wall Street Morning (wallstreetmorning.com)
• Best Quality And EXTRA LOW PRICES! Daily News! Get your cheap Zithromax with high quality is guaranteed! How long to treat chlamydia! (ravenousmonster.com)
• Bioblast Pharma Ltd (ORPN) Seeing Increased Volatility in Session – Evergreen Caller (evergreencaller.com)
• Investors Swarm in on Bioblast Pharma Ltd. (NASDAQ:ORPN) Shares – FLBC News (flbcnews.com)

Shares of Bio Blast Pharma (ORPN) traded up 1.79% during trading on Friday, hitting $0.57. 3,372 shares of the stock were exchanged. The stock has a 50-day moving average of $0.62 and a 200 day moving average of $0.68. The stock’s market cap is $9.34 million. Bio Blast Pharma has a 12-month low of $0.41 and a 12-month high of $1.87.

Separately, ValuEngine downgraded shares of Bio Blast Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

WARNING: This report was first posted by [[site]] and is owned by of [[site]]. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at [[permalink]].

Bio Blast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.